Xcovery Holdings, Inc

Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases. Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com

Oncology,alk positive lung cancer,lung cancer,clinical trials ,alk+ nsclc,kinase inhibitors,oncology research,bio-pharmaceutics,pharmaceutics,cancer,alk inhibitor,ensartinib ,cancer research,pharma ,bio-pharma,clinical studies,research ,investigational agents ,cancer therapy ,hematology,clinical research ,and cancer research

Xcovery holdings, inc operates in the Pharmaceutical manufacturing industry.

Xcovery holdings, inc's revenue is 11m - 100m

Xcovery holdings, inc has 11 - 50 employees.